7 December 2017 - Roche’s Tecentriq will be available on the NHS in England via the Cancer Drugs Fund for certain patients with metastatic urothelial carcinoma.

As expected the National Institute for Health and Care Excellence has now published final guidelines recommending Tecentriq as an option for locally advanced or metastatic urothelial carcinoma in adults, for whom cisplatin-based chemotherapy is unsuitable.

Bladder cancer affects around 10,000 people in the UK each year and when advanced, is linked with poor outcomes, with just 15 percent of patients surviving more than five years.

Read Pharma Times article